Aldeyra Surges as It Challenges FDA Rejection

Aldeyra Therapeutics, Inc. shares moved higher on Tuesday as investors reacted to its intention to file a formal dispute resolution request regarding the reproxalap program.

• ALCX stock held steady today. Where is ALCX stock headed?

ALDX Jumps on FDA Dispute Resolution Plan for Reproxalap

Aldeyra said it plans to submit a formal dispute resolution request to the FDA regarding reproxalap for dry eye disease, a move that could impact the regulatory path and timeline of its late-stage core asset.

In March, the company received a Complete Response Letter from the FDA regarding its new drug application for reproxalap, an investigational treatment for dry eye disease.

FDA Cites Lack of Evidence

The CRL pointed to a "lack of substantial evidence consisting of adequate and well-controlled studies."

The CRL stated that Aldeyra failed to provide substantial evidence of reproxalap's effectiveness in well-controlled studies, raising significant concerns about the reliability of positive results.

The FDA did not recommend additional trials but suggested investigating reasons for certain trial failures and identifying specific populations where the drug may be effective.

Against a backdrop of weak market breadth, this outsized gain suggests traders viewed the news as a company-specific event rather than a "sector-wide" narrative.

ALDX Technical Analysis and Chart Patterns

The healthcare sector has been weak over the past 30 days but still recorded gains over the past 90 days.

Today's divergence looks less like broad rotation into healthcare and more like a single-stock reaction to regulatory dispute resolution news.

ALDX price action: As of Tuesday's writing, Aldeyra Therapeutics shares were up 13.79% at $1.32.